British-Swedish multinational pharmaceutical firm, AstraZeneca, has announced plans to invest $2-bn to expand its long-standing manufacturing footprint in Maryland, US.
This is part of its previously announced $50-bn plan to expand manufacturing and research capabilities in the U.S. by 2030.
Global pharmaceutical companies have been ramping up investments in the United States to expand production capacity, following President Donald Trump’s call for the industry to make more medicines domestically instead of importing active ingredients or finished products.
The latest announcement by AstraZeneca includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials.
AstraZeneca’s Frederick facility currently produces biologics across its portfolio of cancer, autoimmune, respiratory and rare disease treatments. The planned expansion will nearly double commercial manufacturing capacity, allowing increased supply of existing medicines and, for the first time, production across the company’s rare disease portfolio, AstraZeneca said, adding that it will create 200 highly skilled jobs and 900 construction roles.
Its new clinical manufacturing facility in Gaithersburg, which will be fully operational by 2029, will create an additional 100 jobs, retain 400 roles and support a further 1,000 construction-related jobs.
The drugmaker’s previous announcements included a new cell therapy manufacturing facility in Rockville, Maryland, a new drug substance manufacturing facility in Virginia and the expansion of its existing manufacturing facility in Coppell, Texas.
The US is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing and commercial sites.


2 December, 2025 16:54:03 IST 
















